Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zotiraciclib in Advanced Hepatocellular Carcinoma
NCT03738111Phase 1Withdrawn
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Dec 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of zotiraciclib in hepatocellular carcinoma (HCC), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoint: Maximum Tolerated Dose at 28 days. Planned start Dec 2018; status: withdrawn.
02
Drugs
zotiraciclib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03738111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03738111.